[CAS NO. 1082949-68-5] LY2584702 Tosylate
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1082949-68-5]
Store
Catalog
SLK-S7704
Brand
Selleck
CAS
1082949-68-5
DESCRIPTION [1082949-68-5]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 617.62 |
| Molecular Formula | C28H27F4N7O3S |
| SMILES | CN1C=C(C2=CC=C(F)C(C(F)(F)F)=C2)N=C1C3CCN(C4=C5C(NN=C5)=NC=N4)CC3.O=S(C6=CC=C(C)C=C6)(O)=O |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6191 mL | 8.0956 mL | 16.1912 mL |
| 5 mM | 0.3238 mL | 1.6191 mL | 3.2382 mL |
| 10 mM | 0.1619 mL | 0.8096 mL | 1.6191 mL |
| 50 mM | - | - | - |
Description
LY2584702 Tosylate is a selective, ATP-competitive inhibitor with IC50 of 4 nM. Phase 1.
Targets
| p70S6K [1] (Cell-free assay) |
| 4 nM |
In vitro
In HCT116 colon cancer cells, LY2584702 inhibits phosphorylation of the S6 ribosomal protein (pS6) with IC50 of 0.1-0.24 μM. LY2584702 has significant synergistic effects when combined with EGFR inhibitor erlotinib or with the mTOR inhibitor everolimus.
In vivo
LY2584702 (12.5 mg/kg BID), demonstrates significant antitumor efficacy in both U87MG glioblastoma and HCT116 colon carcinoma xenograft models.
References
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.